+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chronic Obstructive Pulmonary Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 -2026

  • ID: 4851532
  • Report
  • February 2019
  • Region: Global
  • 184 pages
  • Transparency Market Research
1 of 2

Global Chronic Obstructive Pulmonary Disease Treatment Market: Overview 

This report analyzes the current and future scenario of the global chronic obstructive pulmonary disease (COPD) treatment market. Rise in prevalence of COPD, increase in the adoption of combination therapy, and surge in awareness about COPD treatment are the key factors anticipated to drive the global market. Additionally, increase in the geriatric population, rise in importance of COPD management, and surge in the number of respiratory care centers contribute to the growth of the global market. According to the Global Initiative for Asthma (GINA) 2018, COPD is the third leading cause of death in the U.S., with large portion of population being undiagnosed.

The global chronic obstructive pulmonary disease treatment market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug class, distribution channel, and region. A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global chronic obstructive pulmonary disease treatment market. 

New drug development by market players through collaborations and increase in research and development expenditure are anticipated to drive the global market. In February 2016, Propeller Health and Novartis Pharma AG entered into collaboration to develop a custom add-on sensor for the Breezhaler inhaler, a device indicated for COPD treatments. This collaboration aims to connect these medications to Propeller’s digital health platform.. 

Global Chronic Obstructive Pulmonary Disease Treatment Market: Key Segments 

In terms of drug class, the global chronic obstructive pulmonary disease treatment market has been segmented into combination, bronchodilators, corticosteroids, phosphodiesterase type 4 inhibitors, mucokineticsm and others. The combination segment has been divided into long acting muscarinic antagonist & inhaled corticosteroids (LAMA-ICS), long acting beta agonist & inhaled corticosteroids (LABA-ICS), triple therapy, and others. The bronchodilators segment has been classified into long acting beta agonist (LABA), short acting beta agonist (SABA), and long acting muscarinic antagonist (LAMA). Based on distribution channel, the market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment is projected to expand at the fastest CAGR due to increase in the number of patients preferring retail pharmacies. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. 

Global Chronic Obstructive Pulmonary Disease Treatment Market: Regional Outlook 

In terms of region, the global chronic obstructive pulmonary disease treatment market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions. 

Companies Mentioned in Report

The report also profiles major players in the global chronic obstructive pulmonary disease treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Key players profiled in the market report include AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline plc, Novartis AG, CHIESI Farmaceutici S.p.A., Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd), Teva Pharmaceutical Industries Ltd, Mylan N.V., and Orion Corporation.

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global COPD Treatment Market

4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global COPD Treatment Market Analysis and Forecast, 2016-2026

5. Key Insights
5.1. Innovative Solutions for COPD Treatment
5.2. Pipeline Analysis

6. Global COPD Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2016-2026
6.3.1. Combination
6.3.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
6.3.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
6.3.1.3. Triple Therapy
6.3.1.4. Others
6.3.2. Corticosteroids
6.3.3. Bronchodilators
6.3.3.1. Long Acting Beta Agonist (LABA)
6.3.3.2. Short Acting Beta Agonist (SABA)
6.3.3.3. Long Acting Muscarinic Antagonist (LAMA)
6.3.4. Phosphodiesterase Type 4 Inhibitors
6.3.5. Mucokinetics
6.3.6. Others
6.4. Market Attractiveness, by Drug Class

7. Global COPD Treatment Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2016-2026
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Market Attractiveness, by Distribution Channel

8. Global COPD Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness By Region

9. North America COPD Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug Class, 2016-2026
9.2.1. Combination
9.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
9.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
9.2.1.3. Triple Therapy
9.2.1.4. Others
9.2.2. Corticosteroids
9.2.3. Bronchodilators
9.2.3.1. Long Acting Beta Agonist (LABA)
9.2.3.2. Short Acting Beta Agonist (SABA)
9.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
9.2.4. Phosphodiesterase Type 4 Inhibitors
9.2.5. Mucokinetics
9.2.6. Others
9.3. Market Value Forecast, by Distribution Channel, 2016-2026
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Value Forecast, by Country, 2016-2026
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country

10. Europe COPD Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2016-2026
10.2.1. Combination
10.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
10.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
10.2.1.3. Triple Therapy
10.2.1.4. Others
10.2.2. Corticosteroids
10.2.3. Bronchodilators
10.2.3.1. Long Acting Beta Agonist (LABA)
10.2.3.2. Short Acting Beta Agonist (SABA)
10.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
10.2.4. Phosphodiesterase Type 4 Inhibitors
10.2.5. Mucokinetics
10.2.6. Others
10.3. Market Value Forecast, by Distribution Channel, 2016-2026
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Value Forecast, by Country/Sub-region, 2016-2026
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region

11. Asia Pacific COPD Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2016-2026
11.2.1. Combination
11.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
11.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
11.2.1.3. Triple Therapy
11.2.1.4. Others
11.2.2. Corticosteroids
11.2.3. Bronchodilators
11.2.3.1. Long Acting Beta Agonist (LABA)
11.2.3.2. Short Acting Beta Agonist (SABA)
11.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
11.2.4. Phosphodiesterase Type 4 Inhibitors
11.2.5. Mucokinetics
11.2.6. Others
11.3. Market Value Forecast, by Distribution Channel, 2016-2026
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Market Value Forecast, by Country/Sub-region, 2016-2026
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region

12. Latin America COPD Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2016-2026
12.2.1. Combination
12.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
12.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
12.2.1.3. Triple Therapy
12.2.1.4. Others
12.2.2. Corticosteroids
12.2.3. Bronchodilators
12.2.3.1. Long Acting Beta Agonist (LABA)
12.2.3.2. Short Acting Beta Agonist (SABA)
12.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
12.2.4. Phosphodiesterase Type 4 Inhibitors
12.2.5. Mucokinetics
12.2.6. Others
12.3. Market Value Forecast, by Distribution Channel, 2016-2026
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Market Value Forecast, by Country/Sub-region, 2016-2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region

13. Middle East & Africa COPD Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2016-2026
13.2.1. Combination
13.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
13.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
13.2.1.3. Triple Therapy
13.2.1.4. Others
13.2.2. Corticosteroids
13.2.3. Bronchodilators
13.2.3.1. Long Acting Beta Agonist (LABA)
13.2.3.2. Short Acting Beta Agonist (SABA)
13.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
13.2.4. Phosphodiesterase Type 4 Inhibitors
13.2.5. Mucokinetics
13.2.6. Others
13.3. Market Value Forecast, by Distribution Channel, 2016-2026
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Market Value Forecast, by Country/Sub-region, 2016-2026
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region

14. Competition Landscape
14.1. Market Player - Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis, by Company, 2017
14.3. Company Profiles
14.3.1. AstraZeneca
14.3.2. Boehringer Ingelheim Pharmaceuticals, Inc.
14.3.3. GlaxoSmithKline plc
14.3.4. Novartis AG
14.3.5. Teva Pharmaceutical Industries Ltd.
14.3.6. Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.)
14.3.7. CHIESI Farmaceutici S.p.A.
14.3.8. Orion Corporation
14.3.9. Mylan N.V.
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll